NEW YORK, April 16 – Transgenomic said Monday it had appointed Gregory Duman as chief financial officer, replacing William Rasmussen, who will stay on as a strategic planner for the company.
Previously, Duman, who has been a member of Transgenomic’s board since March of last year, was the CFO of Artios, a company that provides transaction processing services. He also served as CFO and head of software product development at Transaction Systems Architects.
In his new position, Rasmussen will work directly with Transgenomic’s Chief Executive Officer Collin D’Silva to develop and carry out the company’s business development goals.
“This addition and repositioning strengthens our management team,” D'Silva said in a statement. “Greg Duman brings an outstanding background in financial management to our company and will play a primary role in helping to keep us at the forefront of our industry. And Bill Rasmussen's historical involvement with Transgenomic's goals, objectives and position in the industry make him uniquely qualified to assist with the execution of our business development strategy."
Transgenomic of Omaha, Neb., develops technologies designed to help shed light on the impact of genomic variations on human health. The company produces and markets the Wave System, which is designed to identify DNA mutations using micro-bead technology that can be analyzed using Transgenomic’s Wavemaker software.